Category Archives: Retinal Disease

Progressive Retinal Remodeling In A Transgenic Rabbit Model Of Retinitis Pigmentosa

Leave a reply

This poster was presented today, May 2th at the 2016 Association for Research in Vision and Opthalmology (ARVO) meetings in Seattle, Washington by Rebecca L. Pfeiffer, Bryan W. Jones, and Robert E. Marc.

Posterboard #: D0246

Abstract Number: 2256 – D0246

Author Block: Rebecca L. Pfeiffer1,2 , Bryan W. Jones1,2 , Robert E. Marc1,2 
1 Ophthalmology, University of Utah, Salt Lake City, Utah, United States; 2 Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, Utah, United States

Purpose:Retinal degenerations are a collection of neural disorders, usually precipitated by photoreceptor degeneration. All display progressive metabolic alterations and neural loss following the death of the photoreceptors. Although it has been demonstrated that the metabolism of Müller cells (MCs) is drastically altered in degeneration, the full impact of these changes on surrounding neurons and long-term characterization of remodeling was previously unavailable, due to short lifespans of model organisms.

Methods:Retinal samples were collected from WT and Tg P347L rabbits at ages ranging from 3 months to 6 years. Following enucleation, retinas were divided into fragments and incubated for 10 minutes at 35 degrees C in D-isomers of Glutamate (dE), Glutamine (dQ), or Aspartate (dD) and Ames-bicarbonate medium to explore retinal transport capabilities at each stage of degeneration. Retinas were then fixed in mixed aldehyde buffer and processed for transmission electron microscope connectomics, immunocytochemistry for a range of macromolecules, and computational molecular phenotyping for small molecules (CMP) (J Comp Neurol. 464:1, 2003).

Results:CMP reveals that single metabolic phenotype of MCs splits and diverges into many phenotypes continuously throughout degeneration. Further, all neuronal classes continue to die throughout degeneration. By 6 years, over 90% of neurons are lost, and the remaining glutamatergic neurons have altered metabolic signatures with a large increase in aspartate levels, at times exceeding glutamate. Transport of the D-isomers indicates that glutamate transport capabilities remain intact until the latest stages of degeneration. This may not be true of their GABA transporters.

Conclusions:These results suggest three main conclusions. First, retinal remodeling in degeneration is relentlessly progressive long after all photoreceptors have disappeared. Second, cell types previously thought to remain after degeneration onset, such as ganglion cells, will also ultimately die and the cells not lost often will change their metabolism. The consequence of this metabolic change in neurons is not yet fully explored. Third, the persistent robust glutamate transport capabilities of Müller cells indicate Müller cells can metabolize glutamate despite the massive loss of glutamine synthetase activity, likely unmasking alternate metabolic pathways.

Metabolic Changes During Late Stage Retinal Degeneration In Heterozygous Crx Mutant Cats (CrxRdy/+)

Leave a reply

This abstract was presented today, May 2th at the 2016 Association for Research in Vision and Opthalmology (ARVO) meetings in Seattle, Washington by Laurence Occelli, Bryan W. Jones, and Simon M. Petersen-Jones.

Posterboard #: D0250

Abstract Number: 2260 – D0250

Author Block: Laurence M. Occelli1 , Bryan W. Jones2 , Simon M. Petersen-Jones1 
1 Small Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, United States; 2 Ophthalmology, Moran Eye Center, University of Utah, Salt Lake City, Utah, United States

Disclosure Block:Laurence M. Occelli, None; Bryan W. Jones, None; Simon M. Petersen-Jones, None

Purpose: CRX is a transcription factor essential for normal photoreceptor development and survival. The CrxRdy cat has a spontaneous mutation in Crx. Early disease stages in heterozygous cats (CrxRdy/+) mimics severe Leber’s congenital amaurosis. This study investigated the timing and extent of retinal remodeling in the late stages of retinal degeneration. This will help optimizing the best time for therapies such as retinal prosthesis or optogenetics before retinal rewiring and glial scar become too extensive.

Methods: CrxRdy/+ cats from 6 weeks to 10 years of age were investigated. Eyes were fixed in mixed aldehyde buffer and processed for immunocytochemistry for computational molecular phenotyping for macromolecules and small molecules (CMP) including GABA, glycine, glutamate, taurine, glutamine, aspartate, rhodopsin and red green opsin (J Comp Neurol. 464:1 2003). Samples from 5 retinal areas were collected: area centralis, mid- and far-superior as well as mid- and far-inferior regions.

Results: CMP revealed an absence of red green opsin and a decrease in rhodopsin expression with mislocalization to the photoreceptor inner segments (IS) and cell bodies as early as 6 weeks of age. Inner and outer photoreceptor segments (IS/OS) were present but short at 6 weeks of age. By 12 weeks of age, very few of the stunted OS remained and IS were very short. At that age, Müller cells had become activated initiating hypertrophy, and indicating cell stress. By 5 years of age, a Müller cell seal was clearly present disrupting the retinal lamination via glial columns. Migration of inner nuclear layer cells with inverted and everted cells was also observed from an early age as well as horizontal and amacrine cell sprouting. By 5 years of age, microneuromas formations had developed (Fig.1). Extreme thinning and remodeling was observed in the peripheral retina of older animals and retinal pigment epithelium was lost from the area centralis.

Conclusions: This study indicates that retinal degeneration in the CrxRdy/+ cat retina follows the 3 proposed phases of retinal remodeling. As early as 12 weeks of age, some glial reaction to photoreceptor death was observed followed by formation of a glial seal, rewiring and inner nuclear layer cells migration. Finally, microneuroma formation, severe retinal thinning and remodeling was developed.

A Targeted Inhibitor Of The Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury

Leave a reply

We have a new publication out, A Targeted Inhibitor Of The Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury authored by Alex Woodell, Bryan W. Jones, Tucker Williamson, Gloriane Schnabolk, Stephen Tomlinson, Carl Atkinson and Bärbel Rohrer.

Abstract:
PURPOSE. Morphological and genetic evidence exists that an overactive complement system driven by the complement alternative pathway (CAP) is involved in pathogenesis of age- related macular degeneration (AMD). Smoking is the only modifiable risk factor for AMD. As we have shown that smoke-related ocular pathology can be prevented in mice that lack an essential activator of CAP, we ask here whether this pathology can be reversed by increasing inhibition in CAP.

METHODS. Mice were exposed to either cigarette smoke (CS) or filtered air (6 hours/day, 5 days/week, 6 months). Smoke-exposed animals were then treated with the CAP inhibitor (CR2-fH) or vehicle control (PBS) for 3 months. Spatial frequency and contrast sensitivity were assessed by optokinetic response paradigms at 6 and 9 months; additional readouts included assessment of retinal morphology by electron microscopy (EM) and gene expression analysis by quantitative PCR.

RESULTS. The CS mice treated with CR2-fH showed significant improvement in contrast threshold compared to PBS-treated mice, whereas spatial frequency was unaffected by CS or pharmacological intervention. Treatment with CR2-fH in CS animals reversed thinning of the retina observed in PBS-treated mice as analyzed by spectral-domain optical coherence tomography, and reversed most morphological changes in RPE and Bruch’s membrane seen in CS animals by EM.

CONCLUSIONS. Taken together, these findings suggest that CAP inhibitors not only prevent, but have the potential to accelerate, the clearance of complement-mediated ocular injury. Improving our understanding of the regulation of the CAP pathway is paramount to developing novel treatment approaches for AMD.

Retinal Remodeling in Human Retinitis Pigmentosa

Leave a reply

We have a new publication out (Direct Link, Free Open Access), Retinal Remodeling in Human Retinitis Pigmentosa authored by Bryan W. Jones, Rebecca Pfeiffer, Drew Ferrell, Carl Watt, Michael Marmor and Robert Marc.

Abstract: Retinitis Pigmentosa (RP) in the human is a progressive, currently irreversible neural degenerative disease usually caused by gene defects that disrupt the function or architecture of the photoreceptors. While RP can initially be a disease of photoreceptors, there is increasing evidence that the inner retina becomes progressively disorganized as the outer retina degenerates. These alterations have been extensively described in animal models, but remodeling in humans has not been as well characterized. This study, using computational molecular phenotyping (CMP) seeks to advance our understanding of the retinal remodeling process in humans. We describe cone mediated preservation of overall topology, retinal reprogramming in the earliest stages of the disease in retinal bipolar cells, and alterations in both small molecule and protein signatures of neurons and glia. Furthermore, while Müller glia appear to be some of the last cells left in the degenerate retina, they are also one of the first cell classes in the neural retina to respond to stress which may reveal mechanisms related to remodeling and cell death in other retinal cell classes. Also fundamentally important is the finding that retinal network topologies are altered. Our results suggest interventions that presume substantial preservation of the neural retina will likely fail in late stages of the disease. Even early intervention offers no guarantee that the interventions will be immune to progressive remodeling. Fundamental work in the biology and mechanisms of disease progression are needed to support vision rescue strategies.

Development Of Animal Models Of Local Retinal Degeneration

Leave a reply

Henri Lorach, Jennifer Kung, Corinne Beier, Yossi Mandel, Roopa Dalal, Philip Huie, Jenny Wang, Sengjun Lee, Alexander Sher, Bryan W. Jones, and Daniel Palanker have a new publication, Development of Animal Models of Local Retinal Degeneration (the IOVS direct link is here).

Many of the models of retinal degeneration we explore are genetic.  This project was designed to explore two other alternative approaches to retinal degeneration that are non-genetic and capable of producing highly localized retinal degeneration with precise onset time.

 

In Situ Metabolomic Signatures Of Neuroprotection, Apoptosis, And Microglial Phagocytosis

Leave a reply

This abstract was presented July 1st at the 11th International Converence of the Metabolomics Society at the University of California, Davis by Felix Vazquez-Chona, Drew Ferrell, Bryan W. Jones and Robert E. Marc.

 

Metabolic dysregulation is an early hallmark of neurodegenerative diseases including Alzheimer’s disease and age-related macular degeneration. Mapping metabolic adaptation with cellular resolution and tissue- wide context is crucial to define networks regulating neuronal survival, cell death progression, and immune cell response.

Computational Molecular Phenotyping (CMP) explores the amine metabolome (amino acids and amines). Technically, CMP metabolomics combines amine metabolite trapping, ultrathin microscopy (50-200 nm), immunodetection, pattern recognition, and clustering algorithms. Here we mapped the in situ distribution of over 30 core amine metabolites in retinal cells challenged by light-induced oxidative stress. Metabolomic profiles were phenotyped using ultrastructural, biochemical, and proteomic indices of oxidative stress.

CMP enabled precise visualization of >30 metabolites in every retinal cell. CMP resolved and phenotyped metabolomic profiles to specific degeneration and microglial functional states in the light-damaged retina. Cone photoreceptor survival correlated with enhanced antioxidant glutathione content. Rod photoreceptor apoptosis coincided with rapid depletion of organic osmolytes followed by nuclear import of cationic arginine metabolites. Delay in cell death increased necrosis and DNA damage-induced apoptosis. Microglial chemotaxis enhanced distinct signatures of glutamate and glutathione metabolism; whereas, phagocytosis coinduced classic (M1) and alternative (M2) arginine metabolites of macrophage activation.

CMP discovers and phenotypes cell classes, tracks cell state, and maps disease with single-cell resolution in any tissue or organism.

Webvision Chapter: Retinal Degeneration, Remodeling and Plasticity

Leave a reply

We have published a new chapter in Webvision, Retinal Degeneration, Remodeling and Plasticity that covers the history of the study of retinal degenerations and some of the implications for vision rescue.  Authors are Bryan W. Jones, Rebecca L. Pfeiffer and Robert E. Marc.  It will, like other Webvision chapters evolve over time, which is the whole point of Webvision, but we hope it will generate some discussion.

Retinal Prosthetics, Optogenetics and Photoswitches

Leave a reply

Retinal-Prosthetics-Optogenetics-and-Photoswitches

We have a new publication, Retinal Prosthetics, Optogenetics and Photoswitches in ACS Chemical Neuroscience.  Authors are:  Robert E. Marc, Rebecca L. Pfeiffer, and Bryan W. Jones.

Abstract:

Three technologies have emerged as therapies to restore light sensing to profoundly blind patients suffering from late-stage retinal degenerations: (1) retinal prosthetics, (2) optogenetics, and (3) chemical photoswitches. Prosthetics are the most mature and the only approach in clinical practice. Prosthetic implants require complex surgical intervention and provide only limited visual resolution but can potentially restore navigational ability to many blind patients. Optogenetics uses viral delivery of type 1 opsin genes from prokaryotes or eukaryote algae to restore light responses in survivor neurons. Targeting and expression remain major problems, but are potentially soluble. Importantly, optogenetics could provide the ultimate in high-resolution vision due to the long persistence of gene expression achieved in animal models. Nevertheless, optogenetics remains challenging to implement in human eyes with large volumes, complex disease progression, and physical barriers to viral penetration. Now, a new generation of photochromic ligands or chemical photoswitches (azobenzene-quaternary ammonium derivatives) can be injected into a degenerated mouse eye and, in minutes to hours, activate light responses in neurons. These photoswitches offer the potential for rapidly and reversibly screening the vision restoration expected in an individual patient. Chemical photoswitch variants that persist in the cell membrane could make them a simple therapy of choice, with resolution and sensitivity equivalent to optogenetics approaches. A major complexity in treating retinal degenerations is retinal remodeling: pathologic network rewiring, molecular reprogramming, and cell death that compromise signaling in the surviving retina. Remodeling forces a choice between upstream and downstream targeting, each engaging different benefits and defects. Prosthetics and optogenetics can be implemented in either mode, but the use of chemical photoswitches is currently limited to downstream implementations. Even so, given the high density of human foveal ganglion cells, the ultimate chemical photoswitch treatment could deliver cost-effective, high-resolution vision for the blind.

Metabolic Changes Associated With Müller Cells In A Transgenic Rabbit Model Of Retinal Degeneration

Leave a reply

Retina-RLP

This abstract was presented today at the 2014 Association for Research in Vision and Opthalmology (ARVO) meetings in Orlando, Florida by  Rebecca L. Pfeiffer, Bryan W. Jones and Robert E. Marc.

Purpose: Müller cells play a central role in retinal metabolism via the glutamate cycle. During retinal degeneration Müller cells are among the first to demonstrate changes, reflected in alterations of metabolic signatures and morphology. The timing, extent and regulation of these changes is not fully characterized. To address this issue, we evaluated Müller cell metabolic phenotypes at multiple stages of retinal remodeling.

Methods: Samples were collected post-mortem from both WT and P347L rabbits. The retinas were then divided into fragments, fixed in buffered aldehydes, and embedded in epoxy resins. Tissues were sectioned at 200nm followed by classification with computational molecular phenotyping (CMP) using an array of small and macromolecular signatures (aspartate (D), glutamate (E), glycine (G), glutamine (Q), glutathione (J), GABA (yy), taurine (T), CRALBP, Glutamine Synthetase (GS), and GFAP). Levels of amino acid or protein were quantified by selecting a region of interest either within the Müller cell population or surrounding neurons and evaluating the intensity of the signal within that region.

Results: CMP reveals overall decreases in GS levels over the course of degeneration. Of notable importance, we saw that in regions of near complete photoreceptor loss neighboring Müller cells may express independent variation in metabolic signatures of E, Q, and GS. Also observed in these Müller cells, ratios of GS:E and GS:Q are not consistent with the ratios seen in WT retina. These results are inconsistent with the current models of both E to Q metabolism and microenvironment regulation of Müller cell phenotypes.

Conclusions: These observations indicate two conclusions. First, although the degenerate state of the retina is the likely trigger inducing Müller cells to express altered metabolic signatures, the rate at which the metabolic state changes is not purely a product of the surrounding environment, but also a stochastic change within individual Müller cells. Second, although it is commonly accepted that GS is the primary enzyme which converts Q to E as part of the glutamate cycle, in degenerate retina alternative pathways may be utilized following decrease in GS.

Support: NIH EY02576 (RM), NIH EY015128 (RM), NSF 0941717 (RM), NIH EY014800 Vision Core (RM), RPB CDA (BWJ), Thome AMD Grant (BWJ).